Support of precision medicine through risk-stratification in autoimmune liver diseases – histology, scoring systems, and non-invasive markers

Bossen, Lars; Gerussi, Alessio; Lygoura, Vasiliki; Mells, George; Carbone, Marco; Invernizzi, Pietro

doi:10.1016/j.autrev.2018.02.013

Cited by 29 publications

(25 citation statements)

References 190 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current trends in PBC research focus on identifying non‐invasive markers of disease progression and prognosis 5,6 . Here we present data to support the macrophage activation markers, sCD163 and sMR, as markers of disease progression and prognosis in PBC patients, and thus, as possible surrogate endpoints in future trials of PBC treatments.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis

Bossen

Rebora

Bernuzzi

et al. 2020

Liver International

Self Cite

View full text Add to dashboard Cite

Invernizzi are Joint last authors. Abbreviations: ACLF, acute-on-chronic liver failure; AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, antimitochondrial antibody; CI, confidence interval; C-index, the concordance index; EASL, European Association for the Study of the Liver; ELISA, enzyme-linked immunosorbent assays; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; IQR, interquartile range; LLN, lower limit of normal; LT, liver transplantation; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; sCD163, soluble CD163; sMR, soluble mannose receptor; UDCA, ursodeoxycholic acid; ULN, upper limit of normal. | 1409 BOSSEN Et al.

show abstract

Section: Discussionmentioning

confidence: 74%

“…However, the disease presentation and progression is very heterogeneous and several at‐risk phenotypes have been identified 4 . Thus, identification of non‐invasive risk stratifiers to distinguish between patients with high and low risk of disease progression and need of LT is of paramount importance 5,6 …”

Section: Introductionmentioning

confidence: 99%

Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis

Bossen

Rebora

Bernuzzi

et al. 2020

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…This sensitivity to steroid treatment means it is important to distinguish it from PSC. However, 9%‐15% of patients with PSC will have elevated IgG4 subclasses without fulfilling the criteria for IgG4‐related disease . One small study showed that raised IgG4 in PSC may be associated with aggressive disease, but there are questions over the diagnostic criteria used, and further studies are required to corroborate these findings …”

Section: Prognosis and Risk Stratificationmentioning

confidence: 99%

Precision medicine in primary sclerosing cholangitis

Maurice

Thorburn

2019

J of Digest Diseases

View full text Add to dashboard Cite

Primary sclerosing cholangitis is a rare, complex autoimmune disease in relatively young patients. There is currently no treatment for the disease, resulting in high rates of advanced liver disease leading to death or liver transplantation. However, advances have been made in our understanding of the pathophysiological mechanisms of the disease, particularly from breakthroughs in the underlying genetics. Moreover, large international collaborations have generated important clinical data that have given greater detail on the different disease phenotypes and natural history, generating new risk prediction models. As a result, drug development may be designed to target specific disease mechanisms at known points of the disease natural history. Therefore, more drugs are entering phase II and III development, giving hope that soon patient‐specific treatments may be available to treat this difficult disease.

show abstract

“…1 The nature of AIH is complex and may depend on interactions between genetic susceptibility and environmental triggers. 2 Understanding the exact mechanisms involved in AIH development remains elusive. There is considerable evidence supporting a strong association of type 1 AIH with human leukocyte antigen (HLA) ( Table S1).…”

Section: Introductionmentioning

confidence: 99%

KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis

et al. 2019

View full text Add to dashboard Cite

show abstract

Support of precision medicine through risk-stratification in autoimmune liver diseases – histology, scoring systems, and non-invasive markers

Cited by 29 publications

References 190 publications

Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis

Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis

Precision medicine in primary sclerosing cholangitis

KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis

Contact Info

Product

Resources

About